ADRB3 and hepatocellular carcinoma: Sun et al. showed that systemic adipose tissue browning by β3-AR agonists suppresses tumor growth in hepatocellular carcinoma and pancreatic ductal adenocarcinoma models, highlighting the potential for anti-tumor immunity [8].